CDP323 (under development by UCB S.A. and Biogen) is a compound for oral intake acting against α4-integrin, i.e., it has the same mechanism of action as natalizumab.
CDP323 (koga razvijaju UCB S.A. i Biogen) je jedinjenje za oralnu upotrebu koje deluje protiv α4-integrina, drugim rečima ima isti mehanizam akcije kao natalizumab.